Edwards Lifesciences Q1 sales rise 16.7%, beat estimates

Edwards Lifesciences

23/04/2026 21:28

Overview

Structural heart device maker's Q1 sales grew 16.7%, beating analyst expectations

Adjusted EPS for Q1 beat consensus, reaching $0.78

Company completed $500 mln accelerated share repurchase

Outlook

Edwards Lifesciences raises FY 2026 sales growth guidance to 9%-11% from 8%-10%

Company now expects FY 2026 adjusted EPS of $2.95-$3.05, up from $2.90-$3.05

Edwards projects Q2 2026 sales of $1.66-$1.74 bln and adjusted EPS of $0.70-$0.76

Result Drivers

TAVR GROWTH - Q1 TAVR sales rose 14.4%, driven by healthy U.S. SAPIEN growth, faster growth outside the U.S., and a competitor's exit in Europe

TMTT EXPANSION - TMTT sales rose on double-digit global procedural growth, with higher adoption of EVOQUE and PASCAL therapies

SURGICAL ADOPTION - Surgical sales increased 10.1%, supported by continued adoption of RESILIA therapies and new product launches

Company press release: ID:nBw4xm7Yza

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$1.65 bln
$1.60 bln (25 Analysts)
Q1 Adjusted EPS
Beat
$0.78
$0.73 (24 Analysts)
Q1 EPS
$0.66


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Edwards Lifesciences Corp is $97.00, about 19% above its April 22 closing price of $81.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)